A Phase 1 interventional study of intranasal ketamine in Pharmacokinetics, sponsored by Javelin Pharmaceuticals. Status unknown at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2008-02-29.
Sponsored by Javelin Pharmaceuticals · Phase 1, Interventional, and Treatment
This is an open label, single-center study to determine whether certain nasal medication interact with PMI-150 (intranasal ketamine) 30 mg in healthy adult volunteers and in patients with allergic rhinitis.
To assess separately the effects of a nasal vasoconstrictor (oxymetazoline) and of a nasal steroid on the rate and extent of intranasal absorption of PMI-150 30 mg.
Javelin Pharmaceuticals is the lead sponsor of 14 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
intranasal ketamine
Drug: intranasal ketamine
oxymetazoline plus intranasal ketamine
Drug: intranasal ketamine
intranasal steroid plus intranasal ketamine
Drug: intranasal ketamine
drug interaction
Pharmacokinetics
Time frame: multiple
This study is status unknown, as verified in Aug 2007. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Javelin Pharmaceuticals